Q-Med's interim report for the period January-September 2010 will be published on Friday October 22 at 8:00 am CET. Media and analysts are invited to participate in a press conference at which the report will be presented by Maria Carell, President and CEO and Alexander Kotsinas, CFO. Time: Friday October 22 at 10:30 am CET. Conference id: 87 77 79 To join the conference call dial: Sweden +46 8 505 201 10 or UK +44 (0)20 7162 0077. The slide presentation will be available at www.q-med.com and Investors/Presentations. A recorded version of the presentation will be available for seven working days on tel: Sweden +46 8 505 203 33 or UK +44 (0)20 7031 4064, access code 87 77 79. Financial information 2011 February 11, Year-End report 2010 April 27, Interim Report January - March 2011 July 21, Half Year Report January - June 2011 October 26, Interim Report January - September 2011 Queries should be addressed to: Kristin Ermanbriks, IR Co-ordinator Tel: +46 70 974 90 71 Q-Med AB is a medical device company that develops, manufactures, markets, and sells high quality medical implants for esthetic and medical use. The majority of the products are based on the company's patented technology, NASHA(TM), for the production of stabilized non-animal hyaluronic acid. The product portfolio today contains: Restylane® for filling lines and folds, contouring and creating volume in the face, Macrolane(TM) for body contouring, Durolane(TM) for the treatment of osteoarthritis of the hip and knee joints, Deflux® for the treatment of vesicoureteral reflux, VUR, (a malformation of the urinary bladder) in children, and Solesta® for the treatment of fecal incontinence. Sales are made through the company's own subsidiaries or distributors in over 70 countries. Q‑Med today has about 650 coworkers, with almost 400 at the company's head office and production facility in Uppsala, Sweden. Q-Med AB is listed in the Mid Cap segment of the NASDAQ OMX Nordic. Q-Med AB (publ), Seminariegatan 21, SE-752 28 Uppsala, Sweden. Corporate identity number 556258-6882. Tel: +46 18 474 90 00. Fax: +46 18 474 90 01. E-mail:info@q-med.com. Web: www.q- med.com. [HUG#1450914]
Q-Med AB invites to Q3 conference call
| Quelle: Q-Med AB